La Jolla Institute for Immunology (LJI)

news

The IKAROS protein is crucial for B cell development

5 December 2023 | By Drug Target Review

By mapping the genome, scientists have discovered how IKAROS enables differentiation of hematopoietic stem cells into B cells.

article

New research holds significance in regulating T cell function

8 September 2023 | By Taylor Mixides (Drug Target Review)

New research shows T cells use the nuclear receptor RARα not just for gene regulation, but also to trigger cell surface events that activate them against pathogens and cancer.

news

New computational tool may fuel vaccine development

28 July 2023 | By Izzy Wood (Drug Target Review)

La Jolla biologists harness machine learning and computational tools to make sense of immune system data.

news

SARS-CoV-2 antibodies can bind to two viral targets at once

19 January 2023 | By Izzy Wood (Drug Target Review)

US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.

news

“Slow” vaccine delivery improves immune response to HIV

27 October 2022 | By Ria Kakkad (Drug Target Review)

An experimental HIV vaccine, delivered as increasing doses over several days, led to long-lasting and diverse antibody production in monkeys.

news

Genetic study could influence the development of COVID-19 therapies

23 November 2021 | By Anna Begley (Drug Target Review)

The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.

news

$2.6 million granted to create pan-coronavirus vaccine

25 October 2021 | By Anna Begley (Drug Target Review)

The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.

news

T-cell exhaustion may limit long-term immunity in COVID-19 patients

22 January 2021 | By Hannah Balfour (Drug Target Review)

Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.

news

Researchers emphasise importance of antigen valency for vaccine efficacy

28 August 2020 | By Victoria Rees (Drug Target Review)

Researchers have shown that factoring in valency to vaccine design can improve the number of antibody binding sites on an antigen. 

news

Researchers halt type 1 diabetes onset by denervating the pancreas

27 August 2020 | By Hannah Balfour (Drug Target Review)

Scientists denervated the pancreas using surgery or pharmacological agents to protect it from immune-mediated beta cell destruction, preventing the onset of type 1 diabetes.

news

Potential target to control T follicular helper cells identified

23 June 2020 | By Victoria Rees (Drug Target Review)

A new study shows how the Bcl6 protein can regulate T follicular helper cells, presenting a target for autoimmune and infectious diseases.